Stockreport

ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies [Financial Post (Toronto, Ontario, Canada)]

ProMIS Neurosciences Inc.  (PMN) 
PDF Study results support differentiation of PMN310 from other amyloid-beta-directed antibodies CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 30, 2024 (GLOBE NEWSW [Read more]